Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death.
Yarza R, Bover M, Paredes D, López-López F, Jara-Casas D, Castelo-Loureiro A, Baena J, Mazarico JM, Folgueira MD, Meléndez-Carmona MÁ, Reyes A, Lumbreras C, Paz-Ares L, Díaz-Pedroche C, Gómez-Martín C. Yarza R, et al. Among authors: lumbreras c. Eur J Cancer. 2020 Aug;135:242-250. doi: 10.1016/j.ejca.2020.06.001. Epub 2020 Jun 6. Eur J Cancer. 2020. PMID: 32586724 Free PMC article.
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial.
Gomez-Martin C, Solá C, Hornedo J, Perea S, Lumbreras C, Valentí V, Arcediano A, Rodriguez M, Salazar R, Cortés-Funes H, Hidalgo M. Gomez-Martin C, et al. Among authors: lumbreras c. J Clin Oncol. 2000 May;18(10):2126-34. doi: 10.1200/JCO.2000.18.10.2126. J Clin Oncol. 2000. PMID: 10811678 Clinical Trial.
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, Arcediano A, Yubero A, Ribera F, Gómez C, Trés A, Pérez-Gracia JL, Lumbreras C, Hornedo J, Cortés-Funes H, Paz-Ares L. García-Carbonero R, et al. Among authors: lumbreras c. J Natl Cancer Inst. 2001 Jan 3;93(1):31-8. doi: 10.1093/jnci/93.1.31. J Natl Cancer Inst. 2001. PMID: 11136839 Free article. Clinical Trial.
Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.
Díaz-Pedroche C, Lumbreras C, Del Valle P, San Juan R, Hernando S, Folgueira D, Andrés A, Delgado J, Meneu JC, Morales JM, Moreno E, Aguado JM. Díaz-Pedroche C, et al. Among authors: lumbreras c. Transplant Proc. 2005 Nov;37(9):3766-7. doi: 10.1016/j.transproceed.2005.10.075. Transplant Proc. 2005. PMID: 16386532 Clinical Trial.
Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients.
Díaz-Pedroche C, Lumbreras C, San Juan R, Folgueira D, Andrés A, Delgado J, Meneu JC, Morales JM, Moreno-Elola A, Hernando S, Moreno-González E, Aguado JM. Díaz-Pedroche C, et al. Among authors: lumbreras c. Transplantation. 2006 Jul 15;82(1):30-5. doi: 10.1097/01.tp.0000225830.76907.d0. Transplantation. 2006. PMID: 16861938 Clinical Trial.
187 results